What are the side effects
As a result, Medicaid coverage of GLP-1 drugs for obesity treatment is optional for states, while coverage for other indications (diabetes, cardiovascular disease, and sleep apnea) is required
Cholelithiasis was not reported in placebo-treated patients
instead, their focus is on delivering high protein, fiber, and essential vitamins to help those on GLP-1 therapy maintain adequate nutrition within reduced portion sizes
When TRIUMPH-4 dropped in December 2025, three recommended vendors went out of stock on retatrutide within 72 hours
Conservative escalation is particularly relevant for people who have tried Semaglutide or Tirzepatide before and experienced significant nausea